source
- FDA reviews interim access policy for compounded peptides as Enspryng label expandsThe U.S. Department of Health and Human Services and the Food and Drug Administration have drafted a new interim access policy that would allow compounding pharmacies to use certain peptide drugs u…
- Eli Lilly signals interest in researching and improving psychedelic ibogaine, says neuroscience chiefAt a recent psychedelics conference, Eli Lilly’s neuroscience president Carole Ho announced the company’s interest in studying ibogaine. Ho said Lilly aims to improve the drug’s safety and efficac…